CN Bioinnovations signs agreement to mark World Hepatitis Day, a research agreement with Imperial College London. Collaboration will develop and further validate CN Bio’s in vitro model of hepatitis B liver infection
Oxford, UK, 28 July 2014: CN Bio Innovations Ltd, experts in developing cutting-edge human bionic platforms to test and develop treatments for serious diseases, today announced that it has signed a research agreement with Imperial College London, To advance the development of in vitro models of liver infection based on the company's LiverChip™ platform, the announcement coincides with World Health Organization World Hepatitis Day, further highlighting the ongoing efforts in industry and academia to find treatments for hepatitis and other serious liver diseases.
Validation of an in vitro system for liver infection Dr Marcus Dorner, principal investigator on the new project at Imperial College London, commented: "Unfortunately, currently widely used liver models
Consult now